$17.64 -$0.09 (-0.5%)

04:30 PM EDT on 07/09/20

Cara Therapeutics (NASDAQ:CARA)

CAPS Rating: 3 out of 5

Current Price $17.64 Mkt Cap $829.7M
Open $17.71 P/E Ratio 0.00
Prev. Close $17.73 Div. (Yield) $0.00 (0.0%)
Daily Range $17.36 - $17.88 Volume 329,120
52-Wk Range $8.88 - $27.55 Avg. Daily Vol. 568,570

Caps

How do you think NASDAQ:CARA will perform against the market?

Add Stock to CAPS Watchlist

All Players

82 Outperform
4 Underperform
 

All-Star Players

18 Outperform
3 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:CARA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFBlacknGold (95.19)
Submitted December 13, 2019

From 01/24/2019:"If the development of Korsuva and CR845 proves successful, the company will become worth more than its current valuation. But because it's entirely dependent on a single asset, failure in the clinic would make the company worth far… More

Jflagg1991 (80.01)
Submitted July 19, 2018

Heading down on offering and needs news to stay up

NASDAQ:CARA VS S&P 500 (SPY)

Fools bullish on NASDAQ:CARA are also bullish on:

Fools bearish on NASDAQ:CARA are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CARA.

Recs

0
Member Avatar awisecrackin (59.78) Submitted: 3/24/2020 10:03:16 AM : Outperform Start Price: $11.70 NASDAQ:CARA Score: +18.26

Focused on common annoyances of skin issues like psorisis. Also, has a hand in developing medications based on marijuana. Has a large deal already with a foreign pharm company.

Recs

0
Member Avatar odocoileus (62.24) Submitted: 2/2/2020 5:13:45 PM : Outperform Start Price: $20.37 NASDAQ:CARA Score: -46.47

I got into CARA too early, but so far I haven't seen much to change my opinion on it. They failed their secondary endpoints in their last PH II trial, but they achieved their primary endpoint. The market was fairly harsh on these results. CARA is a one-trick pony, and I think the market tends to be a little more nervous on mixed results for these types of companies. But given that there really is not much else out there for pruritis I don't see these results scuttling FDA approval if the PH III KALM-3 trials are successful. Yeah, big if, but given their prior results, I'm banking on success here. And we should know in a few months. Then it's off to the races. Before concentrating on pruritis, CARA did trials for non-addictive pain relief with some mixed results. This is where the real money is, and if they get this first approval under their belt they should have some breathing room to get back to these trials--if they don't get bought out first.

Recs

1
Member Avatar TMFBlacknGold (95.19) Submitted: 12/13/2019 10:35:41 AM : Outperform Start Price: $14.98 NASDAQ:CARA Score: -1.13

From 01/24/2019:

"If the development of Korsuva and CR845 proves successful, the company will become worth more than its current valuation. But because it's entirely dependent on a single asset, failure in the clinic would make the company worth far less than its current valuation. This is the ultimate binary stock dilemma; it could really go either way and we just don't know yet.

The upside is attractive at a market cap of only $600 million, especially considering Korsuva would hit the ground running with immediate access to roughly 38% of U.S. dialysis treatment centers if it earns marketing approval. Investors aware of the risk might not lose sleep over opening a small position in the business right now. Why not have a little fun with a potential multibagger?"

https://www.fool.com/investing/2019/01/24/is-cara-therapeutics-a-buy.aspx

Leaderboard

Find the members with the highest scoring picks in CARA.

Score Leader

slingermoonsine

slingermoonsine (88.08) Score: +288.41

The Score Leader is the player with the highest score across all their picks in CARA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
bonznstonz < 20 3/17/2016 Outperform 3Y $4.76 +271.64% +54.61% +217.03 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. xmas 70.99 6/29/2016 Outperform 5Y $4.86 +263.99% +52.58% +211.42 1 Comment
TheIzzishWizzy 79.71 6/17/2016 Outperform 5Y $5.05 +250.30% +51.86% +198.44 0 Comment
surfco3 94.47 6/16/2016 Outperform 5Y $5.10 +246.86% +51.45% +195.41 0 Comment
jayzmrmn 76.29 7/12/2016 Outperform 3Y $5.18 +241.51% +46.20% +195.30 1 Comment
dundara 96.71 9/6/2016 Outperform 1Y $5.40 +227.59% +43.68% +183.91 0 Comment
MaBrandao 50.37 3/21/2016 Outperform 1Y $5.35 +230.66% +53.98% +176.67 0 Comment
Clopperc < 20 3/7/2016 Outperform 3W $5.37 +229.42% +57.64% +171.79 0 Comment
Playa14 < 20 8/1/2016 Outperform 5Y $6.00 +194.84% +44.68% +150.16 0 Comment
dollarsandcents1 < 20 9/13/2016 Outperform 5Y $6.01 +194.34% +46.26% +148.08 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CARA.